MedTrace Logo

Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

NCT00070239 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-12-16

No results posted yet for this study

Summary

This phase I trial is studying the side effects and best dose of alvocidib in treating patients with metastatic or unresectable refractory solid tumors or hematologic malignancies. Drugs used in chemotherapy, such as alvocidib, work in different ways to stop cancer cells from dividing so they stop growing or die.

Conditions

  • Hematopoietic/Lymphoid Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

alvocidib

Given IV

OTHER

pharmacological study

Correlative studies

RADIATION

fludeoxyglucose F 18

Correlative studies

OTHER

fluorine F 18 fluorothymidine

Correlative studies

PROCEDURE

positron emission tomography

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Geoffrey Shapiro · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00070239 on ClinicalTrials.gov